Online citations, reference lists, and bibliographies.
← Back to Search

FJoint AAD-NPF Guidelines Of Care For The Management And Treatment Of Psoriasis With Topical Therapy And Alternative Medicine Modalities For Psoriasis Severity Measures.

Craig A. Elmets, N. Korman, Elizabeth Farley Prater, Emily B. Wong, Reena N. Rupani, D. Kivelevitch, A. Armstrong, Cody J. Connor, K. Cordoro, D. Davis, B. E. Elewski, J. Gelfand, K. Gordon, Alice B Gottlieb, D. H. Kaplan, A. Kavanaugh, Matthew Kiselica, Daniela Kroshinsky, M. Lebwohl, C. Leonardi, Jason Lichten, H. Lim, N. Mehta, A. Paller, S. Parra, Arun L. Pathy, Michael P Siegel, B. Stoff, B. Strober, J. Wu, Vidhya Hariharan, A. Menter
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine (AM) will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults.
This paper references
10.1111/jdv.12576
Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)
D. Hägg (2015)
Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
A. Menter (2013)
10.1001/jamadermatol.2014.4305
Association Between Malignancy and Topical Use of Pimecrolimus.
D. Margolis (2015)
10.1016/J.JAAD.2004.07.011
Tacrolimus ointment is effective for facial and intertriginous psoriasis.
M. Lebwohl (2004)
Adjuvant 1388 role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot 1389 randomized open-label study
N Cassano (2010)
Effects of Curcuma 1634 extract and visible light on adults with plaque pso riasis. European journal of dermatology
M Carrion-Gutierrez (2015)
LLC receiving fees and/or honoraria; as a speaker for Abbvie
1111 Sympathetic nerve blocks for the management of postherpetic neuralgia -19 years of 1112 pain clinic experience
H Takahashi
Research Techniques Made S imple: Itch Measurement in Clinical 1823 Trials
S Erickson (2019)
The National Psoriasis 1723 Foundation Psoriasis Score (NPF-PS) system versus t he Psoriasis Area Severity Index 1724 (PASI) and Physician's Global Assessment (PGA): a c omparison
AB Gottlieb (2003)
Novartis 1874 Pharmaceuticals Corp
Celgene Ingelheim
10.3109/09546634.2011.565017
Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study
G. Vena (2012)
10.1046/j.1365-2133.2003.05378.x
Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis
E. Mazzotti (2003)
10.1097/00006534-199702000-00099
Adverse effects of topical corticosteroid use.
I. Turpin (1997)
10.1016/S0190-9622(96)90280-7
Effects of psychologic intervention on psoriasis: a preliminary report.
R. Zachariae (1996)
A retrospective study of 1453 the teratogenicity of dermatological coal tar produ cts
ME Franssen (1999)
Novartis 1988 Pharmaceutical Corp., and Pfizer, Inc., receiving grant and/or research funding; as an 1989 investigator for Eli Lilly and Company, and UCB receiving honoraria
Amgen Abbvie
Sienna Biopharmaceuticals, and Wyeth Labs receiving honoraria; as a consultant for
Novartis
FAAD served as an investigator for Celtaxsys, Inc. receiving fees
Benjamin Stoff
Validity and 1759 reliability of patient reported outcomes used in psoriasis: results from two randomized 1760 clinical trials. Health Qual Life Outcomes
R Shikiar
High prevalence of celiac disease in 1585 psoriasis
V Ojetti (2003)
The validity and 1762 responsiveness of three quality of life measures in the assessment of psoriasis patients: 1763 results of a phase II study
R Shikiar (2006)
Vanda Pharmaceuticals, and Vioment receiving grants/research funding; as an advisory board 1856 member for Foundation for Research & Education of Dermatology, LEO Pharma
Think beyond the Skin: 2014 Canadian Expert 1727 Opinion Paper on Treating to Target in Plaque Psoriasis
W Gulliver (2015)
Pharmaceuticals North America receiving fees; as a consultant for 1983
U S Insights
10.1016/J.JDERMSCI.2006.05.006
Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial--comparison to physician's estimations.
S. Kreft (2006)
10.1159/000369615
Association between Coeliac Disease and Psoriasis: Italian Primary Care Multicentre Study
Rudi De Bastiani (2015)
10.1684/ejd.2010.1013
Comparison of two different dose combinations of calcipotriol/hydrocortisone ointment used once daily for the treatment of psoriasis vulgaris on the face and body.
J. Ortonne (2010)
10.1001/archderm.112.9.1245
Tachyphylaxis to topically applied steroids.
A. du Vivier (1976)
10.1016/J.JAAD.2004.04.012
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.
R. Langley (2004)
10.1111/j.1346-8138.2011.01487.x
Femoral head osteonecrosis after long‐term topical corticosteroid treatment in a psoriasis patient
H. Takahashi (2012)
10.1111/j.1468-3083.2012.04523.x
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy
E. Castela (2012)
XBiotech receiving stock options; as a speaker for AbbVie, Eli Lilly, and Janssen Biotech receiving 1901 honoraria; as a principal investigator/investigator for Abbott Laboratories
Evaluation of the Physician 1737 Global Assessment and Body Surface Area Composite T ool for Assessing Psoriasis 1738 Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM
KC Duffin (2017)
10.1111/jdv.13132
Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment
C. Chow (2015)
Psychological 1596 stress and psoriasis: experimental and prospective correlational studies. Acta Derm 1597 Venereol Suppl (Stockh)
L Gaston (1991)
Galderma Laboratories LP, receiving no compensation and as a member of the data safety 1917 monitoring board for Hapten Sciences receiving fees
10.4103/0378-6323.72455
Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails.
S. Handa (2010)
10.1155/2013/673078
Add-On Effect of Chinese Herbal Medicine Bath to Phototherapy for Psoriasis Vulgaris: A Systematic Review
Jason Jingjie Yu (2013)
10.1007/S10227-001-0006-0
Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis
L. Stein (2001)
10.1016/j.jaad.2013.09.009
Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation.
D. Butler (2014)
Promius Pharma LLC, Sienna 1985 Pharmaceuticals, UCB, and Wyeth Labs receiving honoraria; as a principal investigator for
Janssen Amgen
A pilot study of hypnosi s in the treatment of patients with 1594 psoriasis
F Tausk (1999)
Comparing 1340 clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 1341 0.064% ointment for the treatment of moderate to se vere plaque psoriasis
A Menter (2009)
Castle Creek Pharma, Celgene Corporation, Chameleon Communications
Bridgebio Pharma (1999)
Steering Committee for Celgene receiving fees
Fish Oi l and Perioperative Bleeding
E Akintoye (2018)
Visual anal ogue scale: evaluation of the instrument 1806 for the assessment of pruritus
A Reich (2012)
Novartis Company), and Sun Pharmaceutical Industries Ltd. receiving research and/or 2043 grant funding
Sandoz
Regeneron, Science 37, Inc., and Valeant receiving honoraria; as a speaker for
Inc Pfizer
Validity and 1759 reliability of patient reported outcomes used in ps oriasis: results from two randomized 1760 clinical trials
R Shikiar (2003)
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
K. C. Duffin (2017)
10.1056/NEJM199306243282504
Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis.
E. Søyland (1993)
10.1016/j.jaad.2013.12.018
Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.
M. Lebwohl (2014)
10.1111/j.1468-3083.2009.03214.x
Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris
G. Tiplica (2009)
10.1111/ajd.12353
Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study
Cassandra Chaptini (2016)
10.1111/j.1600-0625.2009.00903.x
Emollient for maintenance therapy after topical corticotherapy in mild psoriasis
S. Seité (2009)
10.1016/S0140-6736(19)30116-3
Chinese herbal remedy found to contain steroids and antifungals
K. F. Mose (2019)
10.1016/J.JAAD.2005.12.028
Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity.
S. Jacob (2006)
A random ized, double-blind, placebo1063 controlled study of clobetasol propionate 0.05% foa m in the treatment of nonscalp 1064 psoriasis
M Lebwohl (2002)
Va lidation of the Psoriasis Symptom 1744 Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom 1745 severity
DM Bushnell (2013)
A 52-we ek randomized safety study of a 1289 calcipotriol/betamethasone dipropionate two-compoun d product 1290 (Dovobet/Daivobet/Taclonex) in the treatment of pso riasis vulgaris
K Kragballe (2006)
Life q uality assessment among patients 1785 with atopic eczema
EA Holm (2006)
1065 10. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment 1066 effect than betamethasone dipropionate in topical psoriasis therapy
M Lebwohl (2002)
FAAD served as a consultant/advisory board member for AbbVie
L Craig (1953)
Tr eatment of severe scalp psoriasis: 1088 from the Medical Board of the National Psoriasis Fo undation
CS Chan (2009)
Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
A. Tirado-Sánchez (2012)
10.1016/j.jaad.2013.09.010
Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.
J. Murase (2014)
10.1016/j.jaad.2019.08.049
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
A. Menter (2019)
10.1016/j.jaad.2013.06.027
Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review.
A. Mason (2013)
10.1016/S0926-9959(97)89359-2
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
M. Lebwohl (1998)
10.1080/09546634.2016.1215405
Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris
C. Pedersen (2017)
A pilot 1776 quality-of-life instrument for pruritus
NS Desai (2008)
Novartis, Pfizer, Inc., and UCB receiving honoraria; as a consultant for AbbVie
Co
Saf ety and Efficacy of a Fixed Combination 1379 Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque 1380 Psoriasis: A Pooled Analysis of Two Phase 3 Studies
JL Sugarman (2018)
Correlation of the vas oconstriction assay and clinical activity 1051 in psoriasis
RC Cornell (1985)
No impact of fis h oil supplements on bleeding risk: a 1559 systematic review
KM Begtrup (2017)
as a consultant for Genzyme receiving fees; as a principal investigator for AbbVie
Psoriasi s prevalence among adults in the 1043 United States
TD Rachakonda (2014)
CSACI position stat ement: safety of topical calcineurin 1215 inhibitors in the management of atopic dermatitis i n children and adults. Allergy Asthma 1216 Clin Immunol
AO Segal (2020)
10.1007/s00403-013-1426-6
No association between vitamin D intake and incident psoriasis among US women
J. Merola (2013)
10.1016/j.jaad.2008.04.027
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
G. Jemec (2008)
10.1096/fj.04-2664fje
The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria
A. McGill (2005)
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis.
A. Menter (2011)
10.1007/s00403-010-1080-1
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz (2010)
10.1111/j.1346-8138.1998.tb02487.x
Combination Therapy with Low‐Dose Etretinate and Eicosapentaenoic Acid for Psoriasis Vulgaris
K. Danno (1998)
Consensu s document on the evaluation and 1657 treatment of moderate-to-severe psoriasis: Psoriasi s Group of the Spanish Academy of 1658 Dermatology and Venereology
E Dauden (2016)
A n evidence-based review of the 1433 efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis
JB Slutsky (2010)
FAAD served as a consultant for Amgen
Amy S Paller (1997)
Calcitrio l sh ws greater persistence of treatment 1066 effect than betamethasone dipropionate in topical p soriasis therapy
JM Camarasa (2003)
FAAD served as a consultant for AbbVie
B Kenneth
Facilitation of 1942 International Dermatology Education, Inozyme Pharma
Cara Therapeuthics (1943)
Prevalence of antigliadin 1580 antibodies in patients with psoriasis is not elevat d compared with controls
KF Kia (2007)
Topical combination 1323 therapy with vitamin D3 and corticosteroid ointment for palmoplantar pustulosis: A 1324 prospective, randomized, left-right comparison stud y
M Muro (2016)
XBiotech receiving grants and/or research funding; as 1931 an advisory board member for Amgen, Celgene Corporation
Inc Rhizen
10.1111/1346-8138.13215
Antinuclear antibody formation following administration of anti‐tumor necrosis factor agents in Japanese patients with psoriasis
K. Yanaba (2016)
10.1111/j.1365-2133.2009.09589.x
Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis
E. Dommasch (2010)
10.1111/j.1365-2133.2006.07725.x
Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten‐free diet
G. Michaëlsson (2007)
10.3109/09546630903214175
Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: An immunohistochemical study
H. M. J. van der Velden (2010)
10.1111/j.1468-3083.2004.01186.x
A double‐blind, placebo‐controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris
E. Paulsen (2005)
Topical salicylic acid interferes with UVB therapy for psoriasis.
B. Kristensen (1991)
10.5603/AIT.2014.0039
Sympathetic nerve blocks for the management of postherpetic neuralgia - 19 years of Pain Clinic experience.
M. Malec-Milewska (2014)
Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
C. Leonardi (2015)
Stiefel a GsK company, UCB, and Warner Chillcott receiving other financial 1962 benefits (fee for service
Biopharmaceuticals
The available evidence was evaluated using a unified system called the Strength of 2075
P soriasis patients with antibodies to gliadin 1592 can be improved by a gluten-free diet
G Michaelsson (2000)
R pid regression of psoriasis in a coeliac 1644 patient after gluten-free diet. A case report and r eview of the literature. Digestion
G Addolorato (2003)
receiving no compensation; and as an advisory board 2008 member for Menlo Therapeutics receiving honoraria
Regeneron Pharma
Duration of impr ovement in psoriasis after treatment 1170 with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of 1171 maintenance treatments
M Lebwohl (2001)
Rapid regression of psoriasis in a coeliac 1644 patient after gluten-free diet. A case report and review of the literature
G Addolorato (2003)
Fluocinol one acetonide topical oil for scalp 1075 psoriasis
M Pauporte (2004)
Inc. receiving honoraria; and in another position as a member of the Scientific 1845
Calcipotriene ointment 0.00 5% for psoriasis: a safety and efficacy 1223 study
A Highton (1995)
10.1001/jamadermatol.2016.1009
Safety of Topical Corticosteroids in Pregnancy.
Ching-Chi Chi (2016)
10.1016/j.jaad.2013.03.031
A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
M. Lebwohl (2013)
10.1111/j.1365-2133.2009.09586.x
The 5‐D itch scale: a new measure of pruritus
S. Elman (2010)
Dioxins and polychlorinated 1547 biphenyls (PCBs) in fish oil dietary supplements: o ccurrence and human exposure in the 1548 UK
AR Fernandes (2006)
Produ ct of the Physician Global Assessment 1741 and body surface area: a simple static measure of p soriasis severity in a longitudinal 1742 cohort
JA Walsh (2013)
Fish Oil and Perioperative Bleeding. Circ 1557 Cardiovasc Qual Outcomes
E Akintoye (2018)
Topical treatments for chronic 1303 plaque psoriasis
AR Mason (2013)
Joint Americ an Academy of Dermatology-National 1315 Psoriasis Foundation guidelines of care for the man agement and treatment of psoriasis 1316 with phototherapy
CA Elmets (2019)
Feasibility and Utility
B Strober (2019)
Efficacy, safety, an d cost of Goeckerman therapy compared 1464 with biologics in the treatment of moderate to seve r psoriasis
R de Miguel (2009)
M easurement Properties of the Psoriasis 1750 Symptom Inventory Electronic Daily Diary in Patient s with Moderate to Severe Plaque 1751 Psoriasis
HN Viswanathan (2017)
Topical tacrolimus 1194 ointment combined with 6% salicylic acid gel for pl aque psoriasis treatment
CL Carroll (2005)
LCD plus NB-UVB reduces time to impro vement of psoriasis
J. Bagel (2020)
MD, FAAD served as speaker for Nutrafol receiving honoraria
Reena N Rupani
Viswanat h n HN. Reliability and validity of the 1747 psoriasis symptom inventory in patients with modera te-to-severe psoriasis
DA Revicki (2014)
Vitae Pharmaceuticals, and Verrica receiving honoraria; as a speaker/educator for Expanscience 2005 receiving honoraria; as a principal investigator for AbbVie
(2006)
Nonantistreptococcal interventions for acute 1521 guttate psoriasis or an acute guttate flare of chro nic psoriasis
A Maruani (2019)
Catabasis Pharmaceuticals, Inc. receiving honoraria; in another role for DermiPsor receiving 1914 honoraria; and in another role for XBiotech receiving stock options
10.1111/j.1440-0960.2012.00877.x
The evaluation of the clinical effect of topical St Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: A pilot study
P. Najafizadeh (2012)
10.1016/S0190-9622(96)90722-7
Effect of UVB phototherapy and oral calcitriol (1,25-dihydroxyvitamin D3) on vitamin D photosynthesis in patients with psoriasis.
J. H. Prystowsky (1996)
10.2340/00015555-1809
Implementing best practice in psoriasis: a Nordic expert group consensus.
K. Kragballe (2014)
10.1038/jid.2013.318
Responsiveness to change and interpretability of the simplified psoriasis index.
L. Chularojanamontri (2014)
10.1016/j.phymed.2014.02.013
Efficacy and safety of Indigo naturalis extract in oil (Lindioil) in treating nail psoriasis: a randomized, observer-blind, vehicle-controlled trial.
Yin-Ku Lin (2014)
10.2147/PTT.S126281
Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management
E. Haneke (2017)
Treatment go als for moderate to severe psoriasis: an 1691 Australian consensus
C Baker (2013)
Postoperative pain intens ity assessment: a comparison of four scales 1819 in Chinese adults
L Li (2007)
Measure 410 (Psoriasis: Clinical Response to Systemic 1666 Medications
American Academy
Ass ociation between coeliac disease and 1587 psoriasis: Italian primary care multicentre study. Dermatology
R De Bastiani (2015)
Calcipotriol plus 1282 betamethasone dipropionate gel compared with tacalc itol ointment and the gel vehicle 1283 alone in patients with psoriasis vulgaris: a random ized, controlled clinical trial
RG Langley (2011)
Psoriasis Foundation guidelines of care for the management and treatment of psoriasis 1316 with phototherapy
(2019)
Vehicle Controlled Clinical Study to Assess the 1167 Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of 1168 Plaque Psoriasis
Multicenter (2017)
Inc. receiving honoraria; as a consultant for
Xenoport Xbiotech
Sol-Gel Technologies, Stiefel a GSK company
Sanofi (2003)
Persistent organic 1554 pollutants in fish oil supplements on the Canadian market: polychlorinated biphenyls and 1555 organochlorine insecticides
DF Rawn (2009)
10.1111/j.1365-2133.1993.tb03338.x
Highly purified omega‐3‐polyunsaturated fatty acids for topical treatment of psoriasis. Results of a double‐blind, placebo‐controlled multicentre study
H.‐H. HENNEICKE‐VON ZEPELIN (1993)
10.1111/j.1365-2133.1993.tb11852.x
Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis
M. Kanzler (1993)
10.1007/s11136-013-0384-y
Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity
J. Cappelleri (2013)
Prevalence, correlates and 1813 characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm 1814 Venereol
U Matterne (2011)
Vali d t on and response to treatment of a 1780 pruritus self-assessment tool in patients with mode rate to severe psoriasis
A Gottlieb (2010)
The role of salicylic acid in the t r atment of psoriasis
M. Lebwohl (1999)
MD has no relationships to disclose
Cody Connor
Ome ga-3 fatty acid-based lipid infusion in 1518 patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo1519 controlled, multicenter trial
P Mayser (1998)
MD, FAAD has no relationships to disclose
Sylvia L Parra
10.1111/j.1365-2133.2010.09791.x
A phase IIIb, multicentre, randomized, double‐blind, vehicle‐controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study
D. Thąci (2010)
10.1111/j.1600-0536.2007.01118.x
Allergic contact dermatitis to Aloe vera
Márcia Ferreira (2007)
10.1001/ARCHDERM.142.9.1138
1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
A. Kreuter (2006)
Factitious hypertension with mineralocorticoid excess in an infant.
P. de Stefano (1983)
Glaucoma from topical c orticosteroids to the eyelids
HM Garrott (2004)
Investigator-masked compariso n of tazarotene gel q.d. plus 1173 mometasone furoate cream q.d. vs. mometasone furoat e cream b.i.d. in the treatment of 1174 plaque psoriasis
JY Koo (2001)
Tacrolimus for the manageme nt of psoriasis: clinical utility and 1218 place in therapy
N Malecic (2016)
Effect of regular 1535 consumption of oily fish compared with white fish o n chronic plaque psoriasis
PM Collier (1993)
Evaluati on of halobetasol propionate ointment 1057 in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled 1058 studies
J Bernhard (1991)
Celgene Corporation, Dermira, Dr. Reddy's Laboratory, Eli Lilly and Company
Squibb
10.1016/j.jaad.2008.12.032
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
A. Menter (2009)
10.1034/j.1600-0846.2003.00042.x
Objective assessment of involved surface area in patients with psoriasis
Young-Min Yune (2003)
10.1016/j.jid.2016.06.633
Validation and Banding of the ItchyQuant: A Self-Report Itch Severity Scale.
Caitlin G. Haydek (2017)
10.1002/lsm.22122
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single‐blind, intrapatient left‐to‐right controlled study
Y. Huang (2013)
10.1016/S0190-9622(96)90352-7
Oral calcitriol (1,25-dihydroxyvitamin D3) does not augment UVB phototherapy for plaque psoriasis.
J. H. Prystowsky (1996)
Safety and efficacy of oral calcitriol 1566 (1,25-dihydroxyvitamin D3) for the treatment of pso riasis
A Perez (1996)
Think bey ond the Skin: 2014 Canadian Expert 1727 Opinion Paper on Treating to Target in Plaque Psori a is
W Gulliver (2015)
Oral c urcumin in the treatment of moderate to 1637 severe psoriasis vulgaris: A prospective clinical t ri l
SK Kurd (2008)
Associat ion Between Topical Corticosteroid 1122 Use and Type 2 Diabetes in Two European PopulationBased Adult Cohorts
YMF Andersen
Utilization patterns of traditional medicine in 1502 Taiwan and South Korea by using national health ins urance data
CW Huang (2011)
Inc. receiving grants and/or research funding
Eviden ce-based recommendations to assess 1686 psoriasis severity: systematic literature review an d expert opinion of a panel of 1687 dermatologists
C Paul (2010)
Zinc fact sheet for professionals
Health Nio (2019)
Safety of topical 1134 corticosteroids in pregnancy
CC Chi (2015)
Comparativ e effects of calcipotriol (MC903) 1228 solution and placebo (vehicle of MC903) in the trea tment of psoriasis of the scalp
C Green (1994)
FAAD served as an investigator for AbbVie
April W Armstrong
Comparison of three methods for 1714 measuring psoriasis severity in clinical studies (P art 1 of 2): change during therapy
C Chow (2015)
MD served as an investigator for Regeneron receiving no compensation
M R Dawn
Sun Pharmaceutical Industries receiving no compensation; as an investigator for 2025
Sienna
10.1016/S0190-9622(96)90620-9
Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3 for the treatment of psoriasis
M. Dahl (1996)
10.1080/10590501.2016.1166826
Aloe vera: A review of toxicity and adverse clinical effects
Xiaoqing Guo (2016)
10.1111/j.1365-2133.2008.08680.x
A study examining inter‐rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index
J. Berth-Jones (2008)
10.1111/ddg.12396
Topical long‐term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice
M. Augustin (2014)
10.3109/09546634.2014.906033
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses*
C. Mamolo (2015)
10.2340/00015555-1237
Patients' visual analogue scale: a useful method for assessing psoriasis severity.
I. Flytström (2012)
Femoral head osteonecrosis after topical corticosteroid therapy.
A. El Maghraoui (2001)
10.1038/jid.2009.389
No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema.
J. Roelofzen (2010)
10.3109/09546634.2012.687087
Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis
Y. Okubo (2014)
10.1016/j.jaad.2017.06.162
Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data
A. Gottlieb (2017)
Pimecrolim us cream 1% in the treatment of 1185 intertriginous psoriasis: a double-blind, randomize d study
C Gribetz (2004)
High-concen tration (20 mug g(-)(1) ) tacalcitol 1247 ointment in the treatment of facial psoriasis: an 8 -week open-label clinical trial
JW Choi (2010)
The role of fish oil in 1538 psoriasis. A randomized, double-blind, placebo-cont rolled study to evaluate the effect of 1539 fish oil and topical corticosteroid therapy in psor iasis
AK Gupta (1990)
Novan (receiving 1849 no fees)
Celgene Squibb
FAAD served as a consultant for Boehringer Ingelheim
E Boni
Applic at on of the Itch Severity Score in 1793 patients with moderate-to-severe plaque psoriasis: Clinically important difference and 1794 responder analyses
CM Mamolo (2015)
Ef ficacy and safety of calcipotriol (MC 903) 1225 ointment in psoriasis vulgaris. A randomized, doubl e- lind, right/left comparative, 1226 vehicle-controlled study
L Dubertret (1992)
FAAD served as a consultant for Aditum Bio
Mark Lebwohl
Principia Biopharma, and UCB receiving honoraria; as an advisory board member for Dr
10.1007/s11655-012-1020-3
A randomized controlled single-blind clinical trial on 84 outpatients with psoriasis vulgaris by auricular therapy combined with optimized Yinxieling Formula (银屑灵优化方)
Chuan-jian Lu (2012)
ItchyQoL bands: pilot clinical 1808 interpretation of scores
EM Love (2015)
10.1185/03007995.2010.541005
Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris
P. V. D. van de Kerkhof (2011)
10.1007/s40257-019-00458-2
Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council
B. Strober (2019)
10.1007/BF00184491
A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis
F. Grimminger (2004)
10.1016/j.jaad.2008.06.041
Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation.
R. E. Kalb (2009)
Potent topical steroid in a Chinese herbal cream.
B. Wood (1997)
10.2165/00128071-200708050-00005
Prevalence of Antigliadin Antibodies in Patients with Psoriasis is Not Elevated Compared with Controls
K. Kia (2007)
Dermatology Life Quality I ndex (DLQI)--a simple practical 1765 measure for routine clinical use. Clinical and experimental dermatology
AY Finlay (1994)
Management of 1505 psoriasis with Aloe vera extract in a hydrophilic c ream: a placebo-controlled, double1506 blind study
TA Syed (1996)
Evaluating daily 1550 exposure to polychlorinated biphenyls and polybromi nated diphenyl ethers in fish oil 1551 supplements
JT Ashley (2010)
Positive effect of modified Goeckerman regimen on 1461 quality of life and psychosocial distress in moderate and severe psoriasis. Acta Derm 1462 Venereol
E Chern (2011)
Durable derma tology life quality index improvements 1711 in patients on biologics associated with psoriasis reas and severity index: a longitudinal 1712 study
C Chaptini (2016)
Reddy's Laboratories
Bristol-Myers Squibb
Proactive treatment 1140 with calcipotriol reduces recurrence of plaque psor iasis
K Ito (2016)
Valeant Pharmaceuticals International, Valeant Pharmaceuticals North America LLC
Ucb Teva
Biopharmaceuticals receiving grants; as an advisory 1991 board member for Abbott Labs, AbbVie, Boehringer Ingelheim, Eli Lilly and Company
Abbott Labs (1992)
Tazaroten e plus UVB phototherapy in the 1368 treatment of psoriasis
JY Koo (2000)
Clinical study 1151 results of desoximetasone spray, 0.25% in moderate to s vere plaque psoriasis
L Kircik (2013)
Acupuncture th rapies for psoriasis vulgaris: a 1608 systematic review of randomized controlled trials
M Coyle (2015)
A randomized, double-blind, multicente r trial comparing fluticasone propionate
M. James (2001)
The risk of 1210 malignancy associated with psoriasis
D Margolis (2001)
10.1046/j.1365-2133.1999.02617.x
Measurement of body surface area involvement in atopic eczema: an impossible task?
Charman (1999)
10.1002/ptr.5640
Effects of Turmeric (Curcuma longa) on Skin Health: A Systematic Review of the Clinical Evidence
A. Vaughn (2016)
10.1046/j.1365-2133.1997.18561949.x
Application of machine vision to assess involved surface in patients with psoriasis
L. Savolainen (1997)
Treatment o f psoriasis vulgaris by oral 1492 administration of yin xie ping granules--a clinical report of 60 cases
C Shan (2006)
1995 and as an independent contractor for Prime Education receiving fees
A trial of oral zinc 1576 supplementation in psoriasis
NP Burrows (1994)
MD, FAAD has no relationships to disclose
Elizabeth A Farley Prater
and XBiotech receiving no compensation; as a consultant for
Double-blind, placebo1542 controlled study to evaluate the efficacy of fish o il and low-dose UVB in the treatment of 1543 psoriasis
AK Gupta (1989)
MD has no relationships to disclose
Jason Lichten
Karyopharm Therapeutics receiving no compensation
10.1016/S0190-9622(98)70594-8
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis.
M. Lebwohl (1998)
Interactions between 1313 calcipotriene and ultraviolet light
M Lebwohl (1997)
MD, FAAD has no relationships to disclose
L Arun
10.4103/0378-6323.44302
Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis.
I. Kaur (2008)
10.2340/00015555-1246
Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus.
N. Q. Phan (2012)
10.2310/7750.2009.08082
Update on Intralesional Steroid: Focus on Dermatoses
R. N. Richards (2010)
10.1371/journal.pone.0208569
Utilization patterns of traditional medicine in Taiwan and South Korea by using national health insurance data in 2011
Ching-Wen Huang (2018)
honoraria; as a principal investigator for AbbVie
Celgene Abbvie (1927)
Regeneron Pharmaceuticals, Inc., 1839 and Sanofi receiving honoraria; and as a data safety member for AbbVie
Eli Abbvie
Treatm n of psoriatic nails with tazarotene 1370 cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study
D Rigopoulos (2007)
Efficacy and tolerability of a 1253 cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a 1254 controlled comparison with calcipotriene (calcipotriol) cream
P Singh
Valeant Pharmaceuticals North 1197 America LLC
UCB, and Vitae receiving honoraria; as a speaker for AbbVie
(1956)
Celgene Corporation, Coronado Biosciences, Immune Control
Boehringer Amgen (1903)
Comparative study of calcipotriol (0.005%) ointment 1361 and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian 1362 journal of dermatology, venereology and leprology
I Kaur (2008)
1222 69. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy 1223 study. Calcipotriene Study Group
N Malecic
Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
S. Silver (2013)
10.1001/ARCHDERM.1989.01670140083015
Psoriasis and vitamin D3. A review of our experience.
S. Morimoto (1989)
10.1111/ajd.12280
Inter‐observer reliability of the PASI in a clinical setting
S. Cabrera (2015)
10.1111/ijd.12645
The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis
A. Naegeli (2015)
10.3109/09546634.2015.1083935
Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
J. Koo (2016)
10.1016/S0149-2918(98)80091-X
Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
J. Koo (1998)
MD has served as a speaker for Eli Lilly and Company receiving honoraria; and 1923 has a first-degree relative employed by Boehringer Ingelheim
Dario Kivelevitch
A controlled t rial of acupuncture in psoriasis: no 1487 convincing effect. Acta Derm Venereol
B Jerner (2020)
FAAD served as a consultant for Abbott Labs
Alan Menter (1979)
Efficacy and tolerability of a 1253 cosmetically acceptable coal tar solution in the tr eatment of moderate plaque psoriasis: a 1254 controlled comparison with calcipotriene (calcipotr i l) cream
MB Alora-Palli (2010)
Efficacy and safety of Indigo naturalis extract in oil 1484 (Lindioil) in treating nail psoriasis: a randomized
Y K Lin
10.2340/00015555-1096
Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis.
Erick Chern (2011)
10.1111/ijd.12788
Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population
Li Ma (2016)
10.1016/0190-9622(92)70299-U
Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study.
L. Dubertret (1992)
10.2340/0001555577154156
A controlled trial of acupuncture in psoriasis: no convincing effect.
B. Jerner (1997)
A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
S. Feldman (2013)
10.1038/jid.2011.162
Psoriasis in a nationwide cohort study of patients with celiac disease.
J. Ludvigsson (2011)
10.1080/09546634.2017.1328098
Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis
Karina Koo (2017)
10.3109/09546634.2012.759639
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity
M. Martin (2013)
One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study.
J. Jekler (1992)
Ortho Dermatologics, Sun Pharmaceuticals Ltd., and UCB receiving honoraria
Inc
Tacrolimus 1207 ointment is more effective than pimecrolimus cream in adult patients with moderate to 1208 very severe atopic dermatitis
AB Fleischer (2007)
FAAD has no relationships to disclose
Daniela Kroshinsky
and UCB receiving 1957 honoraria; and as a principal investigator for Actavis
Eli Corporation
An evidence-based model was used, and evidence was obtained using a search of the 2057
10.1136/annrheumdis-2013-203860
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
M. Schoels (2014)
10.3109/09546639009086743
Vitamin D3 and psoriasis: A randomized double-blind placebo-controlled study
M. A. Siddiqui (1990)
Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis.
Irina Brouda (2010)
Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05.
L. S. Stein Gold (2016)
10.1016/j.jaad.2014.03.017
Diet and psoriasis, part II: celiac disease and role of a gluten-free diet.
Bhavnit K Bhatia (2014)
10.1111/j.1365-2133.2006.07736.x
Itch Severity Scale: a self‐report instrument for the measurement of pruritus severity
C.J. Majeski (2007)
10.1016/S0190-9622(97)80398-2
Tazarotene gel: efficacy and safety in plaque psoriasis.
G. Weinstein (1997)
Association Between Topical Corticosteroid 1122 Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. Diabetes 1123 Care
Ymf Andersen
Objective asse s ment of involved surface area in 1672 patients with psoriasis
YM Yune (2003)
Pfizer Inc., and Principa receiving honoraria/fees; and in another role for Janssen
(1937)
A systematic review of treatments 1529 for guttate psoriasis
RJ Chalmers (2001)
Europ ean S3-guidelines on the systemic 1689 treatment of psoriasis vulgaris
D Pathirana (2009)
Zinc fact sheet for professionals. https://ods.od.nih.gov/factsheets/Zinc1578 HealthProfessional
Health NIo (2019)
Reliability and validity of the 1747 psoriasis symptom inventory in patients with moderate-to-severe psoriasis
D A Revicki (2014)
The spectrum of 1119 oculocutaneous disease: Part II. Neoplastic and dru g-related causes of oculocutaneous 1120 disease
A Day (2014)
Effect of dietary 1526 supplementation with n-3 fatty acids on clinical ma nifestations of psoriasis
A Bjorneboe (1988)
10.1016/j.jep.2009.09.030
Expression of the psoriasis-associated antigen, Pso p27, is inhibited by traditional Chinese medicine.
Ping Song (2010)
Salicylic Acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis.
L. Kircik (2011)
10.1111/bjd.12557
Plant extracts for the topical management of psoriasis: a systematic review and meta‐analysis
S. Deng (2013)
10.1111/j.1600-0781.2011.00602.x
The influence of psoriatic plaques pretreatment with crude coal tar vs. petrolatum on the efficacy of narrow‐band ultraviolet B: a half‐vs.‐half intra‐individual double‐blinded comparative study
M. Abdallah (2011)
10.4103/0019-5154.139872
Topical Steroid-Damaged Skin
A. Abraham (2014)
10.1080/000155500750012153
Dermatology life quality index: data from Danish inpatients and outpatients.
R. Zachariae (2000)
Using Pruritus Grading System for Measurement of Pruritus in Patients with Diseases Associated with Itch
Firas A Al-Qarqaz (2012)
10.1111/j.1365-2133.1991.tb04952.x
Measurement of involved surface area in patients with psoriasis
B. Ramsay (1991)
A randomized, double-blind, multicenter trial comparing fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, applied twice daily for 4 weeks in the treatment of psoriasis.
M. James (2001)
Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
R. Scher (2001)
10.1016/j.jaad.2009.09.049
Validation and response to treatment of a pruritus self-assessment tool in patients with moderate to severe psoriasis.
A. Gottlieb (2010)
Double -blind, randomised, multicentre, 1429 parallel group study comparing a 1% coal tar prepar ation (Exorex) with a 5% coal tar 1430 preparation (Alphosyl) in chronic plaque psoriasis
M Goodfield (2004)
FAAD served as a consultant for Valeant receiving honoraria; as a 1843 consultant for Pfizer, Inc. receiving fees; as an advisory board member for Anacor 1844
M Kelly
Stress ma nagement for psoriasis patients: The 1603 effectiveness of biofeedback and relaxation techniq ues
G Keinan (1995)
Psychological 1596 stress and psoriasis: experimental and prospective corr lational studies
L Gaston (1991)
PhD served as a consultant for Abbott Laboratories
Alice B Gottlieb
Responsiveness to change and 1709 interpretability of the simplified psoriasis
L Chularojanamontri (2014)
10.1046/j.1365-4362.1999.00500.x
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
The rationale behind topical vitamin d analogs in the treatment of psoriasis: where does topical calcitriol fit in?
G. Kim (2010)
10.1016/j.urolonc.2013.12.006
Dermatological exposure to coal tar and bladder cancer risk: a case-control study.
J. Roelofzen (2015)
10.1016/0272-0590(89)90324-2
Comparison of fetotoxic effects of a dermally applied complex organic mixture in rats and mice.
R. Zangar (1989)
Matthew Kiselica has no relationships to disclose
and Novartis Pharmaceuticals Corp. receiving grants and/or research 1889 funding; and as an advisory board member for Celgene Corporation
Inc
Combined treatment with low1477 dose cyclosporine and calcipotriol/betamethasone di prop onate ointment for moderate-to1478 severe plaque psoriasis: a randomized controlled op n-label study
GA Vena (2012)
Sanofi-Regeneron, Sun 2020 Pharmaceuticals Industries, and UCB receiving honoraria; as a consultant for Affibody
and Verrica Pharmaceuticals Inc. receiving honoraria; as a 1945 principal investigator or investigator for AbbVie
Theravance Reddy
Turmeric (Curcumin), Zinc, Hypnosis, meditation, stress reduction
A double-blind, randomized clinical trial
KL Akamine (2013)
Valeant Pharmaceuticals International, and Verrica Pharmaceuticals receiving honoraria; as a 1851 principal investigator for AbbVie
Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on August 17, 2020
(2012)
Efficacy and safety of to pical calcineurin inhibitors for the 1204 treatment of atopic dermatitis: meta-analysis of ra ndomized clinical trials
N Abedz (2019)
The effect of addition of 1048 calcipotriol ointment (50 micrograms/g) to acitreti n herapy in psoriasis
PC van de Kerkhof (1998)
Savin RC. Desoximetasone--a new topical corticosteroid: short-and long-term 1071 experiences
B R Keegan (1978)
Treatment of psoriatic nails with tazarotene 1370 cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm 1371 Venereol
D Rigopoulos (2007)
Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey
10.1016/S0140-6736(88)91181-6
A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF FISH OIL IN PSORIASIS
S. B. Bittiner (1988)
10.1186/1710-1492-9-24
CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults
Audrey O Segal (2013)
10.1186/s13063-016-1272-x
Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial
Dan-ni Yao (2016)
Topical Corticosteroids. In: StatPearls
S Gabros (2019)
Immune Pharmaceuticals, Regeneron, Sanofi, Sun Pharma, and Valeant 1935 receiving fees; as an advisory board member/consultant for AbbVie
(1936)
MD, FAAD served as a principal or co-investigator for
W Henry (1965)
UCB, and Valeant, receiving honoraria; in another role for Amgen 1911 receiving grants and/or research funding
AS Nordisk
Pharmaceuticals North America LLC receiving honoraria; and as a principal/investigator for 2040
The co mbination of calcipotriol and 1474 methotrexate compared with methotrexate and vehicle in psoriasis: results of a 1475 multicentre placebo-controlled randomized trial
EM de Jong (2003)
Topical preparation s for the treatment of psoriasis: a 1082 systematic review
J Mason (2002)
Valid t on and Banding of the ItchyQuant: A 1783 Self-Report Itch Severity Scale
CG Haydek (2017)
Desoximetasone--a new topical cortico s er id: short- and long-term 1071 experiences. Cutis
RC Savin (1978)
Comparison of actual 1674 psoriasis surface area and the psoriasis area and s everity index by the human eye and 1675 machine vision methods in following the treatment o f psoriasis
L Savolainen (1998)
Topic al tazarotene vs. coal tar in stable 1359 plaque psoriasis
U Kumar (2010)
Calcipotriol ointmen t. A review of its use in the 1309 management of psoriasis
LJ Scott (2001)
Pharmaceuticals Inc. receiving honoraria; and in another role for Hoffman-La Roche Ltd. 1858 receiving fees
A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis:Psoriasis Area and Severity Index,Physician's Global Assessment and Lattice System Physician's Global Assessment
Nhs Trust (2006)
10.1016/j.jaad.2016.10.017
From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
A. Armstrong (2017)
10.1111/bjd.14464
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis
A. Kimball (2016)
10.1111/j.1468-3083.2012.04524.x
Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review
S. Devaux (2012)
10.1111/jdv.13614
Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council
J. Wu (2016)
10.1016/j.jaad.2009.10.016
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.
D. Levine (2010)
10.1016/j.jaad.2007.12.035
Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial.
S. Kurd (2008)
10.1111/bjd.12393
Topical treatments for chronic plaque psoriasis of the scalp: a systematic review
A. Mason (2013)
PhD served as a consultant for Insmed Incorporated, and Oricula Therapeutics
Michael Siegel (2014)
and UCB receiving 1920 grants/research funding
Eli Corporation
MD served as a principal investigator for AbbVie
Arthur Kavanaugh (1919)
Afecta Pharmaceuticals receiving no compensation; as a speaker for Abbott Labs
(1984)
PhD served as a consultant for AbbVie
E Bruce (2017)
MD, FAAD has no relationships to disclose
Emily B Wong
Celgene Corporation, Eli Lilly and Company, Incyte Corporation, InflaRX GmbH
Squibb
pimecrol imus, 0.005% calcipotriol, and 0.1% 1182 betamethasone in the treatment of intertriginous ps oria is: a double-blind, randomized 1183 controlled study
A Kreuter (2006)
Practicabilit y of combined treatment with 1347 calcipotriol/betamethasone gel (Daivobet(R) Gel) an d improvement of quality of life in 1348 patients with psoriasis
M Sticherling (2013)
Topica l herbal medicine combined with 1481 pharmacotherapy for psoriasis: a systematic review and meta-analysis
S Deng (2013)
Efficacy and safety of fluticasone pr opionate 0.005% ointment in the 1073 treatment of psoriasis
EA Olsen (1996)
10.1111/j.1365-2133.2007.08337.x
A comparison of twice‐daily calcipotriol ointment with once‐daily short‐contact dithranol cream therapy: quality‐of‐life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day‐care setting
J. de Korte (2008)
10.1159/000381225
Acupuncture Therapies for Psoriasis Vulgaris: A Systematic Review of Randomized Controlled Trials
M. Coyle (2015)
10.3109/09546639709160502
A new aqueous dithranol gel for psoriasis: Comparison with placebo and calcipotriol ointment
C. Grattan (1997)
10.1155/2015/283634
Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris
E. Antiga (2015)
10.3109/09546634.2013.800182
Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients
R. Saraceno (2014)
Desoximetasone 0.25% Spray for the Relief of Scaling in Adults With Plaque Psoriasis.
Brian R. Keegan (2015)
10.1111/j.1365-2133.1993.tb03329.x
Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin
G. Michaëlsson (1993)
10.1046/j.1365-4362.1999.00782.x
Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy
Thomas J. Franz (1999)
FAAD served as a consultant for Novartis Pharmaceuticals Corp. 1925 receiving honoraria; as a consultant for Dr. Reddy's Laboratory receiving fees; as a speaker for
J Neil
Aevi Genomic Medicine (receiving stock) and Immunogen (paid to spouse)
Comparati ve evaluation of topical calcipotriol 1250 versus coal tar and salicylic acid ointment in chro nic plaque psoriasis
P Singh (2013)
FAAD served as a consultant for Abbvie
J Jashin
New aspects of itch 1773 pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch 1774 Questionnaire
U Darsow (2001)
Workgroup members listed alphabetically
Efficacy, safety, and cost of Goeckerman therapy compared 1464 with biologics in the treatment of moderate to severe psoriasis
R De Miguel
The efficacy and tolerability of clobetasol 1060 propionate foam 0.05% in the treatment of mild to m oderate plaque-type psoriasis of 1061 nonscalp regions
AB Gottlieb (2003)
Effects of T urmeric (Curcuma longa) on Skin 1573 Health: A Systematic Review of the Clinical Evidenc
AR Vaughn (2016)
Stress managemen t for psoriasis patients: The 1649 effectiveness of biofeedback and relaxation techniq ues
G Keinan (1995)
The reliability of three pso riasis assessment tools: Psoriasis area and 1654 severity index, body surface area and physician glo bal assessment
A Bozek (2017)
UCB receiving honoraria; as consultant/advisory board for AstraZeneca 2030
Sun Pharmaceutical Industries Ltd
Sanofi Regeneron
Proactive treatment in childh ood psoriasis
J Lavaud (2019)
Measurement Properties of the Psoriasis 1750 Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque 1751 Psoriasis. Value Health
H N Viswanathan (2017)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar